Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women

Sexually Transmitted Infections

Volumn 85, Issue 7, 2009, Pages 499-502

  Fairley, C K ^a,b   Hocking, J S ^b   Gurrin, L C ^b   Chen, M Y ^a,b   Donovan, B ^c   Bradshaw, C S ^a,d  

^a ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; AUSTRALIA; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; FEMALE; GENERAL PRACTICE; HEALTH PROGRAM; HETEROSEXUAL MALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; VACCINATION;

ADOLESCENT; ADULT; CHILD; CONDYLOMATA ACUMINATA; FEMALE; HOMOSEXUALITY, MALE; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; MALE; PAPILLOMAVIRUS VACCINES; RETROSPECTIVE STUDIES; VICTORIA; YOUNG ADULT;

EID: 72449210177     PISSN: 13684973     EISSN: 14723263     Source Type: Journal    
DOI: 10.1136/sti.2009.037788     Document Type: Article

References (13)

1. Villa L, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus like particle vaccine in young women: a randomised double blind placebo controlled multi centre phase 11 efficacy trial. Lancet Oncol 2005;6:271-278
2. Koutsky L, Ault KA, Wheeler CM, et al. A controlled trial of human papillomavirs type 16 vaccine. N Engl J Med 2002;347:1645-1651 (Pubitemid 35340782)
3. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia - a randomised controlled trial. Obstet Gynecol 2006;107:18-27. (Pubitemid 43755499)
4. Harper D, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: a follow -up from a randomised controlled trial. Lancet 2006;367:1247-1255
5. Villa L, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16 and 18. Vaccine 2006;24:5571-5583
6. Villa L, Costa RL, Petta CA, et al. high sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow up. Br J Cancer 2006;95:1459-1466
7. The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high grade cervical lesions. N Engl J Med 2007;356:1915-1927 (Pubitemid 46740302)
8. Barr E, Tamms G. Quadrivalent human papilloma vaccine. Clin Infect Dis 2007;45:609-617
9. Giuliano A, Palefsky J. The efficacy of quadrivalent HPV (types 6/11/16/18) vaccine in reducing the incidence of HPV infection and HPV-related genital disease in young men [abstract (SS19-197a)]. EUROGIN 2008 Congress: Joining Forces for Cervical Cancer Prevention; Nice, 2008. http://www.eurogin. com/2008/ EUROGIN2008-LastMinuteAbstracts.pdf (accessed: 15 Sept 2009).
10. Kulasingam S, Connelly L, Conway E, et al. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sexual Health 2007;4:165-175 (Pubitemid 47339645)
11. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomvirus vaccination in the United Kingdom. BMJ 2008;337:a769.
12. Tideman RL, Pitts MK, Fairley CK. Effects of a change from an appointment service to a walk-in triage service at a sexual health centre. Int J STD AIDS 2003;14:793-795
13. Hu D, Goldie S. The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol 2008;198:e1-7.